dc.contributor.author
Wetz, Christoph
dc.contributor.author
Genseke, Philipp
dc.contributor.author
Apostolova, Ivayla
dc.contributor.author
Furth, Christian
dc.contributor.author
Ghazzawi, Sammy
dc.contributor.author
Rogasch, Julian M. M.
dc.contributor.author
Schatka, Imke
dc.contributor.author
Kreissl, Michael C.
dc.contributor.author
Hofheinz, Frank
dc.contributor.author
Grosser, Oliver S.
dc.contributor.author
Amthauer, Holger
dc.date.accessioned
2019-12-13T14:12:33Z
dc.date.available
2019-12-13T14:12:33Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/26251
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-26011
dc.description.abstract
AIM:
Purpose of this study was to evaluate the association of the spatial heterogeneity (asphericity, ASP) in intra-therapeutic SPECT/ CT imaging of somatostatin receptor (SSR) positive metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) for morphological treatment response to peptide receptor radionuclide therapy (PRRT). Secondly, we correlated ASP derived form a pre-therapeutic OctreoScan (ASP[In]) and an intra-therapeutic [177Lu]-SPECT/CT (ASP[Lu]).
MATERIALS AND METHODS:
Data from first therapy cycle [177Lu-DOTA0-Tyr3]octreotate ([177Lu]-DOTATATE)-PRRT was retrospectively analyzed in 33 patients (m = 20; w = 13; median age, 72 [46-88] years). The evaluation of response to PRRT was performed according to RECIST 1.1 in responding lesions [RL (SD, PR, CR), n = 104] and non-responding lesions [NRL (PD), n = 27]. The association of SSR tumor heterogeneity with morphological response was evaluated by Kruskal-Wallis test and receiver operating characteristic curve (ROC). The optimal threshold for separation (RL vs. NRL) was calculated using the Youden-index. Relationship between pre- and intra-therapeutic ASP was determined with Spearman's rank correlation coefficient (ρ) and Bland-Altman plots.
RESULTS:
A total of 131 lesions (liver: n = 59, lymph nodes: n = 48, bone: n = 19, pancreas: n = 5) were analyzed. Lesions with higher ASP values showed a significantly poorer response to PRRT (PD, median: 11.3, IQR: 8.5-15.5; SD, median: 3.4, IQR: 2.1-4.5; PR, median 1.7, IQR: 0.9-2.8; CR, median: 0.5, IQR: 0.0-1.3); Kruskal-Wallis, p<0.001). ROC analyses revealed a significant separation between RL and NRL for ASP after 4 months (AUC 0.85, p<0.001) and after 12 months (AUC 0.94, p<0.001). The optimal threshold for ASP was >5.45% (sensitivity 96% and specificity 82%). The correlation coefficient of pre- and intra-therapeutic ASP revealed ρ = 0.72 (p <0.01). The mean absolute difference between ASP[In] and ASP[Lu] was -0.04 (95% Limits of Agreement, -6.1-6.0).
CONCLUSION:
Pre- and intra-therapeutic ASP shows a strong correlation and might be an useful tool for therapy monitoring.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Pre- and intra-therapeutic ASP
en
dc.subject
Peptide receptor radionuclide therapy
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
e0216781
dcterms.bibliographicCitation.doi
10.1371/journal.pone.0216781
dcterms.bibliographicCitation.journaltitle
PLoS ONE
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.originalpublishername
Public Library of Science (PLoS)
dcterms.bibliographicCitation.volume
14
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
31091247
dcterms.isPartOf.eissn
1932-6203